Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mediwelcome Healthcare Management & Technology Inc. (2159.HK)
Beijing, CN
As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference organization, patient education and screening programs, along with strategic marketing and advisory support. Additionally, the company provides Contract Research Organization (CRO) services, specifically focusing on patient recruitment and clinical data gathering. Furthermore, Mediwelcome manages a mobile application that facilitates internet hospital functionalities, including virtual follow-up consultations for physicians' current patients and electronic prescription services. Its diverse client base includes pharmaceutical firms, medical associations, and various foundations. Established in 2000, Mediwelcome Healthcare Management & Technology Inc. maintains its headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.63% | +8.78% | +20.15% | +35.29% | +37.61% | +270.11% | +85.06% | -31.49% | -57.52% | -57.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Healthcare Information Services: +14.2%+45.6% ★ Q4'25: +84.9% (vs Q4'23)
-
EPS growth Medical - Healthcare Information Services: +43.1%+118.3% ★ Q4'25: +120.3% (vs Q4'23)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%-0.3% Q4'25: -4.8% (vs Q4'23)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+0.4% Q4'25: +1.7% (vs Q4'23)
-
ROIC Medical - Healthcare Information Services: +5.2%+3.0% Q4'25: +37.2% (vs Q4'23)
-
Share dilution Medical - Healthcare Information Services: -0.1%+19.1% Q4'25: +38.2% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×19.40× ★ Q4'25: 2.26× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 4/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-07 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-06 | B- | 2/5 | 1/5 | 3/5 | 4/5 | 1/5 | 2/5 | 3/5 |
| 2026-05-04 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-30 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Liang Wang | Chief Executive Officer & Executive Director | 1M | male |
| Wei Shi | Executive Chairman of the Board | 1M | male |
| Weimin Yang | Executive Vice Chairman of the Board | 937.2K | male |
| Chengying Deng | Executive Director & Chief Financial Officer | 366.3K | female |
| Luyang Zhao | Vice President of Human Resources & Joint Company Secretary | — | female |
| Haidong Jiang | Chief Technology Officer | — | male |
| Ming Mei Chen | Company Secretary | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2159.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
